Only Affymax is public; another potential ESA.
Only Affymax is public; another potential ESA competitor, GlycoFi, was acquired by Merck last year.. These companies include Affymax, FibroGen and Neose. It’s worth remembering that while the storm is currently walloping industry giants like Amgen and J&J, plenty of smaller biotechs that have staked their hopes on getting into the anemia-treatment game could eventually be affected as well.
Original text search at: venturebeat.com/index.php?tag=co%3aamgen